Please login to the form below
Shingrix
This page shows the latest Shingrix news and features for those working in and with pharma, biotech and healthcare.
GSK beats expectations thanks to strong vaccine sales in Q2
However, sales of its shingles jab Shingrix increased by only 1% on a constant currency basis, although the drugmaker is expecting strong growth from the vaccine in the second half of
Latest news
-
GSK’s revenue drops by 18% in Q1 as performance pressures mount
Shingrix. Walmsley pinned GSK’s growth prospects on the launch of its HIV pill Cabenuva, as well as a potential RSV vaccine, currently in phase 3 trials, and a new ... GSK is confident that sales of Shingrix will increase in the second half of the year,
-
Pfizer, Sanofi and others set to increase US drug prices in 2021
Pfizer and Sanofi are planning to keep almost all of their increase at 5% or lower, 3 Axis added, with GSK also increasing their prices of two vaccines, Shingrix and Pediarix,
-
GSK considers more divestments to help R&D push
Looking at the fourth quarter numbers, pharma sales slumped 5% to £4.6bn, but there was an encouraging 18% gain for vaccines to £1.74bn thanks to strong growth for Shingrix,
-
GSK boosts outlook thanks to strong respiratory and vaccine sales
Key Q3 drivers include Shingrix vaccine and asthma drug Nucala. GlaxoSmithKline has raised its profit forecast for the second consecutive quarter thanks to the strong sales of its shingles vaccine Shingrix ... Also bringing the forecast up is GSK’s
-
Shingrix lifts GSK in Q1, but two more vaccines are culled
The decision to drop the two vaccines came as another of GSK’s vaccines – Shingrix for shingles – saw its sales rocket in the first three months of the year, reaching £357m ( ... Shingrix’ performance helped GSK’s vaccine unit to a 23% sales
More from news
Approximately 9 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
contain the adjuvant QS-21 Stimulon. In October 2017 GSK's QS-21 Stimulon herpes zoster vaccine, Shingrix, was approved by the FDA. GSK's malarial vaccine, Mosquirix which also contains
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
-
B2B media account director
-
Competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- MHRA approves second COVID-19 antibody treatment
- Sanofi to buy acne specialist Origimm
- Roche acquires test maker TIB Molbiol
- Merck enters agreement with Hanmi for investigational NASH drug
- AstraZeneca blocks take-private buyout of Sobi
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
No results were found
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
